Comprehensive Analysis of the Molecular Characteristics and Prognosis value of at II-associated Genes in Non-small Cell Lung Cancer

被引：2
作者：
Ren L. [1 ]
Wen X. [2 ]
Liu M. [3 ]
Xiao Y. [4 ]
Leng P. [2 ]
Luo H. [4 ]
Tao P. [5 ]
Xie L. [6 ]
机构：
[1] School of Healthcare Technology, Chengdu Neusoft University, Chengdu
[2] Chongqing Key Lab. of Sichuan-Chongqing Co-Constr. for Diagn. and Treatm. of Infect. Dis. Intgd. Traditional Chinese and W. Med., College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu
[3] Ineye Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu
[4] Department of Clinical Laboratory, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Sichuan, Chengdu
[5] Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Sichuan
[6] The Sichuan Provincial Key Laboratory for Human Disease Gene Study, Department of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu
来源：
Computational and Mathematical Methods in Medicine | 2022年 / 2022卷
关键词：
461.2 Biological Materials and Tissue Engineering - 461.6 Medicine and Pharmacology - 461.9 Biology - 461.9.1 Immunology;
D O I：
10.1155/2022/3106688
中图分类号：
学科分类号：
摘要：
Alveolar type II (AT II) is a key structure of the distal lung epithelium and essential to maintain normal lung homeostasis. Dedifferentiation of AT II cells is significantly correlated with lung tumor progression. However, the potential molecular mechanism and clinical significance of AT II-associated genes for lung cancer has not yet been fully elucidated. In this study, we comprehensively analyzed the gene expression, prognosis value, genetic alteration, and immune cell infiltration of eight AT II-associated genes (AQP4, SFTPB, SFTPC, SFTPD, CLDN18, FOXA2, NKX2-1, and PGC) in Nonsmall Cell Lung Cancer (NSCLC). The results have shown that the expression of eight genes were remarkably reduced in cancer tissues and observably relating to clinical cancer stages. Survival analysis of the eight genes revealed that low-expression of CLDN18, FOXA2, NKX2-1, PGC, SFTPB, SFTPC, and SFTPD were significantly related to a reduced progression-free survival (FP), and low CLDN18, FOXA2, and SFTPD mRNA expression led to a short postprogression survival (PPS). Meanwhile, the alteration of 8 AT II-associated genes covered 273 out of 1053 NSCLC samples (26%). Additionally, the expression level of eight genes were significantly correlated with the infiltration of diverse immune cells, including six types of CD4+T cells, macrophages, neutrophils, B cells, CD8+ T cells, and dendritic cells. In summary, this study provided clues of the values of eight AT II-associated genes as clinical biomarkers and therapeutic targets in NSCLC and might provide some new inspirations to assist the design of new immunotherapies. © 2022 Liping Ren et al.
引用
收藏
相关论文
共 56 条
  • [1] Liang W., Zhao Y., Huang W., Gao Y., Xu W., Tao J., Yang M., Li L., Ping W., Shen H., Fu X., Chen Z., Laird P.W., Cai X., Fan J.B., He J., Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA), Theranostics, 9, 7, pp. 2056-2070, (2019)
  • [2] Herbst R.S., Morgensztern D., Boshoff C., The biology and management of non-small cell lung cancer, Nature, 553, 7689, pp. 446-454, (2018)
  • [3] Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Pineros M., Znaor A., Bray F., Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods, International Journal of Cancer, 144, 8, pp. 1941-1953, (2019)
  • [4] Relli V., Trerotola M., Guerra E., Alberti S., Abandoning the notion of non-small cell lung cancer, Trends in Molecular Medicine, 25, 7, pp. 585-594, (2019)
  • [5] Roointan A., Ahmad Mir T., Ibrahim Wani S., Mati Ur R., Hussain K.K., Ahmed B., Abrahim S., Savardashtaki A., Gandomani G., Gandomani M., Chinnappan R., Akhtar M.H., Early detection of lung cancer biomarkers through biosensor technology: A review, Journal of Pharmaceutical and Biomedical Analysis, 164, pp. 93-103, (2019)
  • [6] Didkowska J., Wojciechowska U., Manczuk M., Lobaszewski J., Lung cancer epidemiology: Contemporary and future challenges worldwide, Annals of Translational Medicine, 4, 8, (2016)
  • [7] Huang Y., Wang J., Zhao Y., Wang H., Liu T., Li Y., Cui T., Li W., Feng Y., Luo J., Gong J., Ning L., Zhang Y., Wang D., Zhang Y., CncRNAdb: A manually curated resource of experimentally supported RNAs with both protein-coding and noncoding function, Nucleic Acids Research, 49, D1, pp. D65-d70, (2021)
  • [8] Lin C., Song H., Huang C., Yao E., Gacayan R., Xu S.M., Chuang P.T., Alveolar type II cells possess the capability of initiating lung tumor development, PLoS One, 7, 12, (2012)
  • [9] Sears C.R., Mazzone P.J., Biomarkers in lung cancer, Clinics in Chest Medicine, 41, 1, pp. 115-127, (2020)
  • [10] Clausen M.M., Langer S.W., Improving the prognosis for lung cancer patients, Acta Oncologica, 58, 8, pp. 1077-1078, (2019)
123456